Literature DB >> 10447317

Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders.

A Lundqvist1, T Tolfvenstam, M Brytting, C M Stolt, K Hedman, K Broliden.   

Abstract

Patients with haematological disorders (n = 100) were examined for prevalence of parvovirus B19 DNA in the bone marrow and serum, irrespective of B19-related symptoms. B19 DNA was studied using 2 nested PCRs and the serum samples were further analysed with B19-specific IgG, IgM and avidity as well as seroreactivity against linear and conformational epitopes of the B19 VP2 antigen. The latter assays specify whether the IgG antibody response represents acute or past B19 infection. B19 DNA was detected in 4 of the 100 bone marrow samples, whereas all the serum samples were B19 DNA negative. None of the 4 B19 DNA positive patients had symptoms typical of B19 infection and serology showed past infection. Furthermore, 2 were still B19 DNA positive in bone marrow more than 1 y after the first sample indicating virus persistence. The seroprevalence for B19 IgG was 59% and 2 patients were B19 IgM positive. Thus, presence of B19 DNA in bone marrow from patients with haematological disorders is not a general finding in seropositive patients. B19 DNA can persist in bone marrow, but in our material this finding showed no clear correlation with symptomatic B19 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447317     DOI: 10.1080/003655499750006128

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

1.  Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals.

Authors:  Erik D Heegaard; Bodil Laub Petersen; Carsten J Heilmann; Allan Hornsleth
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

3.  Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19.

Authors:  T Tolfvenstam; A Oxenius; D A Price; B L Shacklett; H M Spiegel; K Hedman; O Norbeck; M Levi; K Olsen; M Kantzanou; D F Nixon; K Broliden; P Klenerman
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Cytokine responses in acute and persistent human parvovirus B19 infection.

Authors:  A Isa; A Lundqvist; A Lindblom; T Tolfvenstam; K Broliden
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

5.  Pure Red Cell Aplasia due to B19 Parvovirus Infection after Autologous Stem Cell Transplantation.

Authors:  Panagiotis Tsirigotis; Konstantinos Girkas; Christina Economopoulou; Anthoula Bouchla; Nikolaos Papanicolaou; Panagiota Economopoulou; Sotirios Papageorgiou; Vassiliki Pappa; John Dervenoulas
Journal:  Case Rep Transplant       Date:  2011-06-27

6.  Parvovirus B19 in the Context of Hematopoietic Stem Cell Transplantation: Evaluating Cell Donors and Recipients.

Authors:  Bianca E Gama; Vanessa E Emmel; Michelle Oliveira-Silva; Luciana M Gutiyama; Leonardo Arcuri; Marta Colares; Rita de Cássia Tavares; Luis F Bouzas; Eliana Abdelhay; Rocio Hassan
Journal:  Transplant Direct       Date:  2017-10-02

7.  Parvovirus B19-induced hemophagocytic lymphohistiocytosis: Case report and review of the literature.

Authors:  James Kalmuk; Sara Matar; Gong Feng; Edward Kilb; Ming Y Lim
Journal:  Clin Case Rep       Date:  2019-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.